132 related articles for article (PubMed ID: 22177599)
1. Design and synthesis of N-substituted indazole-3-carboxamides as poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors(†).
Patel MR; Pandya KG; Lau-Cam CA; Singh S; Pino MA; Billack B; Degenhardt K; Talele TT
Chem Biol Drug Des; 2012 Apr; 79(4):488-96. PubMed ID: 22177599
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
[TBL] [Abstract][Full Text] [Related]
4. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A
Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526
[TBL] [Abstract][Full Text] [Related]
5. (WO2011057959) indole and indazole derivatives as glycogen synthase activators: a patent evaluation.
Skaltsounis AL; Gaboriaud-Kolar N
Expert Opin Ther Pat; 2011 Dec; 21(12):1925-9. PubMed ID: 21988345
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of substituted 3-amino-N-phenyl-1H-indazole-1-carboxamides endowed with antiproliferative activity.
Maggio B; Raimondi MV; Raffa D; Plescia F; Cascioferro S; Plescia S; Tolomeo M; Di Cristina A; Pipitone RM; Grimaudo S; Daidone G
Eur J Med Chem; 2011 Jan; 46(1):168-74. PubMed ID: 21130540
[TBL] [Abstract][Full Text] [Related]
7. DNA strand breaks and poly(ADP-ribose) synthetase activation in pancreatic islets--a new aspect to development of insulin-dependent diabetes and pancreatic B-cell tumors.
Okamoto H; Yamamoto H
Princess Takamatsu Symp; 1983; 13():297-308. PubMed ID: 6317640
[TBL] [Abstract][Full Text] [Related]
8. Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.
Kumar A; Pathak SR; Ahmad P; Ray S; Tewari P; Srivastava AK
Bioorg Med Chem Lett; 2006 May; 16(10):2719-23. PubMed ID: 16500101
[TBL] [Abstract][Full Text] [Related]
9. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy.
Sharma SS; Kumar A; Kaundal RK
Life Sci; 2008 Mar; 82(11-12):570-6. PubMed ID: 18262571
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Gandhi VB; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Park C; Giranda VL; Penning TD; Zhu GD
Bioorg Med Chem Lett; 2010 Feb; 20(3):1023-6. PubMed ID: 20045315
[TBL] [Abstract][Full Text] [Related]
12. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
[TBL] [Abstract][Full Text] [Related]
13. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.
Dieckmann A; Kriebel M; Andriambeloson E; Ziegler D; Elmlinger M
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):132-8. PubMed ID: 22020669
[TBL] [Abstract][Full Text] [Related]
14. Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP.
Chandak PG; Gaikwad AB; Tikoo K
Phytother Res; 2009 Jan; 23(1):72-7. PubMed ID: 18693296
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries.
Ferraris D; Ko YS; Pahutski T; Ficco RP; Serdyuk L; Alemu C; Bradford C; Chiou T; Hoover R; Huang S; Lautar S; Liang S; Lin Q; Lu MX; Mooney M; Morgan L; Qian Y; Tran S; Williams LR; Wu QY; Zhang J; Zou Y; Kalish V
J Med Chem; 2003 Jul; 46(14):3138-51. PubMed ID: 12825952
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
Schaus JM; Thompson DC; Bloomquist WE; Susemichel AD; Calligaro DO; Cohen ML
J Med Chem; 1998 May; 41(11):1943-55. PubMed ID: 9599243
[TBL] [Abstract][Full Text] [Related]
17. Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation.
Claramunt RM; López C; Pérez-Medina C; Pérez-Torralba M; Elguero J; Escames G; Acuña-Castroviejo D
Bioorg Med Chem; 2009 Sep; 17(17):6180-7. PubMed ID: 19679481
[TBL] [Abstract][Full Text] [Related]
18. Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase.
Arrick DM; Sharpe GM; Sun H; Mayhan WG
Microvasc Res; 2007 Jan; 73(1):1-6. PubMed ID: 16982071
[TBL] [Abstract][Full Text] [Related]
19. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
20. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors.
Iwashita A; Hattori K; Yamamoto H; Ishida J; Kido Y; Kamijo K; Murano K; Miyake H; Kinoshita T; Warizaya M; Ohkubo M; Matsuoka N; Mutoh S
FEBS Lett; 2005 Feb; 579(6):1389-93. PubMed ID: 15733846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
